ClinicalTrials.gg
CompletedNCT04485741Updated Feb 2, 2023

Strados System at Center of Excellence

An observational study in Copd, Asthma and Covid19, sponsored by Strados Labs, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-02-02.

Sponsored by Strados Labs, Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States — 139 open to participants now, 174 under way, 21 of them phase 3. Pulmonary Disease, Chronic Obstructive · United States.

Enrollment
189th of 237
30 · median 171
Started
2020
with 53 others
Observational
238 of 1,280
35 open now
Registered
988th of 1,280
by date

Among the 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, this one is the 189th largest by enrollment of the 237 observational ones that give a count, is one of 54 that started in 2020, is one of 238 observational ones, and was the 988th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

139 of the 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States are open now. Recruiting first, the newest first:

134 more — sign in →

All 139 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, or all of them as a file.
02

Study summary

Listening to breath sounds with the stethoscope/auscultation is used by pulmonary physicians in conjunction with pulmonary function, signs and symptoms, oxygen saturation and diagnostic testing to admit, follow and discharge patients from hospital. Of these, only auscultation routinely ceases upon discharge from Hospital. Healthcare utilization statistics have shown that for more than a decade, readmission after discharge for an exacerbation of COPD or severe asthma (or chronic heart failure) remains a major problem. The Strados System has been designed to extend the range of lung sound recording both geographically and temporally to improve the standard of care when access to continuous monitoring has been replaced by periodic or no monitoring. The primary purpose of this study is to assess the clinical utility of the Strados System in enabling periodic recording and reviewing of breath sounds in patients with chronic respiratory diseases, either in the ICU, or in less continuously monitored settings, including after inpatient discharge.

03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects who are admitted for exacerbation of chronic airway disease (COPD or severe asthma) or for respiratory distress symptoms associated with SARS-COV-2 infection for 1 to 3 weeks to ICU or specialty floor with access to telemedicine monitoring

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Potential study participants will be recruited from within the Einstein Center of Excellence. Individuals who meet all of the following criteria are eligible for enrollment as study participants:

  1. Males and females between the ages of 18-80:

    With documented physician-diagnosed (chronic bronchitis dominant) or severe asthma, as defined either by the American Thoracic Society or the World Health Organization who are admitted for exacerbation, including those with active or suspected SARS-COV-2 infection

    OR

    Who are admitted with respiratory distress symptoms associated with SARS-COV-2 infection

  2. Able to provide
  3. Able to follow study procedures
  4. Clinician assessment of the patient's current SARS-COV-2 status: negative or unlikely to be infected, RTPCR positive, or untested by clinically suspected
  5. Accessible by telephone upon discharge

Exclusion criteria

Exclusion Criteria:

Subjects who meet ANY of the following criteria are not eligible for enrollment:

  1. Inability or unwillingness of the participant to give written
  2. History of adverse reaction or allergy to Tegaderm
  3. Unwillingness or inability to comply with study procedures
  4. Scheduled for thoracic procedure
  5. Inaccessible by telephone post-discharge
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (actual)
Patient registry
No

Interventions

  • DeviceRESP

    The RESP device will be placed on the patient for periodic recording of auscultory sound.

    Also known as: Strados System

06

What researchers measure

Primary outcomes

  1. Clinical utility as assessed by the PI

    To assess the clinical utility of Strados Systems in enabling periodic recording and reviewing of lung breath sounds of inpatients with chronic respiratory diseases in ICU , and less continuously monitored settings.

    Time frame: Periodic recording over 12 to 24 hours

Secondary outcomes

  1. Clinical utility as assessed by other clinicians

    Time frame: Periodic recording over 12 to 24 hours

  2. Correlation of RESP data with other measures of patient status.

    Time frame: Periodic recording over 12 to 24 hours

07

Study locations

1 site
  • Albert Einstein Medical Center
    Philadelphia, Pennsylvania 19141, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Dec 2021, 15 months.

Of 120 industry-sponsored observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's 15 months is below that.

Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2020
First posted
Jul 24, 2020
StartActual
Sep 23, 2020
Primary completionActual
Dec 28, 2021
CompletionActual
Dec 31, 2021
Last update
Feb 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04485741
Lead sponsor
Strados Labs, Inc.
Responsible party
Sponsor
First posted
Jul 24, 2020
Start date
Sep 23, 2020
Primary completion
Dec 28, 2021
Completion
Dec 31, 2021
Last update
Feb 2, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion